Partnered

The market outlook is full of uncertainty and pitfalls. Experts weigh in on how to mitigate risks.

While the benefits of AI are clear, the amount data sets needed for effective AI integration is proving to be a challenge. This is particularly true for cell therapy companies as they are eagerly seeking ways to reduce development costs. Two experts at Charles River Laboratories provide insights by giving their takeaways from their own AI integrations.

Building and scaling biopharma workforces can go beyond recruiting permanent employees to include fractional workers and consultants. A Slone Partners executive discusses how these blended workforces operate, highlighting the strategic benefits.

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), reveals both promising developments and significant concerns shaping the advanced therapies sector’s trajectory through 2025 and beyond. This interview was conducted with support from Tozaro.

While Quantum computing has been reported to be five years away for many years now, companies are preparing for it by setting foundations with AI in development.

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies.

Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.

AI offers tremendous potential but there are critical and time-consuming flaws in black box AI predictions.

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.